| B68 | Risk of hospitalization among children who were HIV exposed and uninfected (cHEU) in Montreal, Canada | E-poster | HIV-exposed uninfected children |
| A23 | RNA-directed gene therapy protects CD4+ T cells during HIV challenge and delays virus rebound post-ART in humanized mice | On-demand oral abstract session | Gene therapy |
| A10 | RNAi screening of the RabGTPase family of proteins reveals a critical role of Rab35 during HIV-1 replication | E-poster | T cell depletion and reconstitution, and immune ageing |
| A5 | Robust anti-viral immune responses at the placenta during early gestation limit in utero HIV infection and replication | E-poster | Innate immunity |
| D96 | Robust progress in ARV optimization for older adolescents and adults despite COVID-19 | E-poster | Antiretroviral therapy, including treatment as prevention |
| B80 | Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIV | On-demand oral abstract session | Immune responses against SARS-CoV2 in PLWHIV |
| A17 | Role of cellular immune activation in enrichment of deleted HIV proviruses during antiretroviral therapy | E-poster | Host cellular factors and latency |
| A17 | Role of multiple NF-κB motifs in HIV-1 LTR in modulating gene expression noise and fate-switch | E-poster | Host cellular factors and latency |
| D90 | Safer sexual health awareness, attitudes and practices among HIV key populations in the early months of the COVID-19 pandemic in the Philippines | E-poster | Awareness, information, and risk perception regarding HIV transmission and prevention |
| B36 | Safety and pharmacokinetics of islatravir in study participants with severe renal insufficiency | E-poster | Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring |